JP2023510199A5 - - Google Patents
Info
- Publication number
- JP2023510199A5 JP2023510199A5 JP2022540702A JP2022540702A JP2023510199A5 JP 2023510199 A5 JP2023510199 A5 JP 2023510199A5 JP 2022540702 A JP2022540702 A JP 2022540702A JP 2022540702 A JP2022540702 A JP 2022540702A JP 2023510199 A5 JP2023510199 A5 JP 2023510199A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antagonist
- human
- ilt4
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062956469P | 2020-01-02 | 2020-01-02 | |
| US62/956,469 | 2020-01-02 | ||
| PCT/US2020/065799 WO2021138079A1 (en) | 2020-01-02 | 2020-12-18 | Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510199A JP2023510199A (ja) | 2023-03-13 |
| JP2023510199A5 true JP2023510199A5 (https=) | 2023-12-22 |
Family
ID=76687248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540702A Pending JP2023510199A (ja) | 2020-01-02 | 2020-12-18 | Ｐｄ－１アンタゴニスト、ｉｌｔ４アンタゴニストおよびレンバチニブまたはその塩を使用する組合せ癌治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230058779A1 (https=) |
| EP (1) | EP4084794A4 (https=) |
| JP (1) | JP2023510199A (https=) |
| KR (1) | KR20220137007A (https=) |
| CN (1) | CN115151258A (https=) |
| AU (1) | AU2020416715A1 (https=) |
| BR (1) | BR112022013143A2 (https=) |
| CA (1) | CA3166571A1 (https=) |
| MX (1) | MX2022008216A (https=) |
| WO (1) | WO2021138079A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230050449A1 (en) * | 2019-12-20 | 2023-02-16 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| US20250011453A1 (en) * | 2021-07-20 | 2025-01-09 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| WO2023077521A1 (en) * | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| CN114191547A (zh) * | 2021-12-23 | 2022-03-18 | 中山大学 | 仑伐替尼与pd-1单抗联用在制备抗肝癌药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| RU2714233C2 (ru) * | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| TWI796329B (zh) * | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
-
2020
- 2020-12-18 US US17/790,543 patent/US20230058779A1/en active Pending
- 2020-12-18 KR KR1020227026590A patent/KR20220137007A/ko not_active Withdrawn
- 2020-12-18 BR BR112022013143A patent/BR112022013143A2/pt not_active Application Discontinuation
- 2020-12-18 MX MX2022008216A patent/MX2022008216A/es unknown
- 2020-12-18 EP EP20910875.2A patent/EP4084794A4/en active Pending
- 2020-12-18 JP JP2022540702A patent/JP2023510199A/ja active Pending
- 2020-12-18 CN CN202080098004.1A patent/CN115151258A/zh active Pending
- 2020-12-18 CA CA3166571A patent/CA3166571A1/en active Pending
- 2020-12-18 WO PCT/US2020/065799 patent/WO2021138079A1/en not_active Ceased
- 2020-12-18 AU AU2020416715A patent/AU2020416715A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510199A5 (https=) | ||
| JP2023515675A5 (https=) | ||
| JP2018070648A5 (https=) | ||
| JP2021514969A5 (https=) | ||
| JP2021513540A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2014511179A5 (https=) | ||
| JP2019536806A5 (https=) | ||
| JP2015534579A5 (https=) | ||
| JP2022548947A5 (https=) | ||
| JP2015532292A5 (https=) | ||
| HRP20240626T1 (hr) | Bispecifična antitijela protiv ceacam5 i cd3 | |
| JP2017514795A5 (https=) | ||
| JP2017522307A5 (https=) | ||
| JP2017507900A5 (https=) | ||
| JP2022512851A5 (https=) | ||
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2011506483A5 (https=) | ||
| JP2018527383A5 (https=) | ||
| JP2022543062A5 (https=) | ||
| JP2019524714A5 (https=) | ||
| AU2017201367A1 (en) | Prolonged inhibition of interleukin-6 mediated signaling | |
| JP2019532970A5 (https=) | ||
| JP2023516441A5 (https=) |